VCM
JSPR icon

Vivaldi Capital Management’s Jasper Therapeutics JSPR Stock Holding History

Vivaldi Capital Management’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,512
Closed -$150K – 355
2021
Q1 		$150K Buy
+1,512
New +$154K 0.03% 275

Other funds holding JSPR

MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return
TCM
Tenor Capital Management New York $6.49B AUM 3.01% 1-Year Est. Return
FTCM
Fir Tree Capital Management New York $21.8M AUM 1.61% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return
WRBC
W.R. Berkley Corp Greenwich, Connecticut $1.86B AUM 14.44% 1-Year Est. Return
KIM
Karpus Investment Management Pittsford, New York $3.21B AUM 6.83% 1-Year Est. Return
RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
DCM
Dupont Capital Management Wilmington, Delaware $879M AUM 29.99% 1-Year Est. Return
BCM
Basso Capital Management Stamford, Connecticut $163M AUM 21.95% 1-Year Est. Return

Vivaldi Capital Management's JSPR Position: Q2 2021 in Review

Vivaldi Capital Management sold out of Jasper Therapeutics (JSPR) in Q2 2021, closing a stake of 1,512 shares — an estimated $150K sold.

Vivaldi Capital Management first reported a position in JSPR in Q1 2021 and held it in 1 quarter. The position peaked at $150K in Q1 2021. 57 funds tracked by Wall St. Rank hold JSPR as of Q2 2021.

  • Vivaldi Capital Management reported no remaining Jasper Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Vivaldi Capital Management sold 1,512 Jasper Therapeutics shares in Q2 2021, an estimated $150K.
  • Vivaldi Capital Management first reported a position in Jasper Therapeutics in Q1 2021 and held it in 1 quarter.
  • Vivaldi Capital Management's Jasper Therapeutics position peaked at $150K in Q1 2021.
  • 57 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q2 2021.

Based on Vivaldi Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.